Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Nov;116(5):2496–2502. doi: 10.1111/j.1476-5381.1995.tb15101.x

Comparative behavioural profile of centrally administered tachykinin NK1, NK2 and NK3 receptor agonists in the guinea-pig.

O Piot 1, J Betschart 1, I Grall 1, S Ravard 1, C Garret 1, J C Blanchard 1
PMCID: PMC1909059  PMID: 8581290

Abstract

1. The NK1 tachykinin receptor agonists, septide, [Sar9,Met(O2)11]SP and [Pro9]SP produced locomotor hyperactivity (10-20 min) when injected intracerebroventricularly (i.c.v.) in the guinea-pig. The most potent in eliciting this hyperactivity was septide (from 0.63 to 5 micrograms), compared to [Sar9,Met(O2)11]SP, which was active at 2.5 and 5 micrograms and [Pro9]SP which induced a non-significant increase even at 10 micrograms. 2. Wet-dog shakes were elicited by septide, [Sar9,Met(O2)11]SP and [Pro9]SP injected by the i.c.v. route in the guinea-pig. [Sar9,Met(O2)11]SP, active from 0.16 to 2.5 micrograms was more potent than septide (active at 1.25 micrograms) and [Pro9]SP (active at 0.63 micrograms) in eliciting such behaviour. To a lesser extent, grooming was also observed after injection of these agonists. 3. The NK2 tachykinin receptor agonist, [Lys5,MeLeu9,Nle10]NKA(4-10), up to the dose of 10 micrograms i.c.v. had no effect in the guinea-pig. It neither modified locomotor activity nor induced a characteristic behavioural response. At higher doses (20 micrograms), some toxic effects were noted. 4. The NK3 tachykinin receptor agonist, senktide, contrasts with the NK1 receptor agonists in that it elicited only wet-dog shakes, at doses ranging from 0.32 to 1.25 micrograms. It neither modified locomotor activity (1 microgram) nor induced grooming (up to 5 micrograms) in the guinea-pig. 5. To our knowledge, these results are the first demonstration that the guinea-pig could be useful to differentiate tachykinin agonists on the basis of their behavioural profile, distinct from those obtained in mice and rats.

Full text

PDF
2496

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnt J., Hyttel J., Larsen J. J. The citalopram/5-HTP-induced head shake syndrome is correlated to 5-HT2 receptor affinity and also influenced by other transmitters. Acta Pharmacol Toxicol (Copenh) 1984 Nov;55(5):363–372. doi: 10.1111/j.1600-0773.1984.tb01996.x. [DOI] [PubMed] [Google Scholar]
  2. Beresford I. J., Birch P. J., Hagan R. M., Ireland S. J. Investigation into species variants in tachykinin NK1 receptors by use of the non-peptide antagonist, CP-96,345. Br J Pharmacol. 1991 Oct;104(2):292–293. doi: 10.1111/j.1476-5381.1991.tb12423.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Boden P., Woodruff G. N. Presence of NK3-sensitive neurones in different proportions in the medial habenula of guinea-pig, rat and gerbil. Br J Pharmacol. 1994 Jul;112(3):717–719. doi: 10.1111/j.1476-5381.1994.tb13135.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brent P. J., Johnston P. A., Chahl L. A. Increased plasma catecholamines and locomotor activity induced by centrally administered substance P in guinea-pigs. Neuropharmacology. 1988 Jul;27(7):743–748. doi: 10.1016/0028-3908(88)90084-6. [DOI] [PubMed] [Google Scholar]
  5. Chahl L. A., Johnston P. A. Effect of the nonpeptide NK-1 receptor antagonist CP-96,345 on the morphine withdrawal response of guinea-pigs. Regul Pept. 1993 Jul 2;46(1-2):373–375. doi: 10.1016/0167-0115(93)90090-u. [DOI] [PubMed] [Google Scholar]
  6. Chassaing G., Lavielle S., Loeuillet D., Robilliard P., Carruette A., Garret C., Beaujouan J. C., Saffroy M., Petitet F., Torrens Y. Selective agonists of NK-2 binding sites highly active on rat portal vein (NK-3 bioassay). Neuropeptides. 1991 Jun;19(2):91–95. doi: 10.1016/0143-4179(91)90137-8. [DOI] [PubMed] [Google Scholar]
  7. Culman J., Tschöpe C., Jost N., Itoi K., Unger T. Substance P and neurokinin A induced desensitization to cardiovascular and behavioral effects: evidence for the involvement of different tachykinin receptors. Brain Res. 1993 Oct 15;625(1):75–83. doi: 10.1016/0006-8993(93)90139-e. [DOI] [PubMed] [Google Scholar]
  8. Dam T. V., Quirion R. Pharmacological characterization and autoradiographic localization of substance P receptors in guinea pig brain. Peptides. 1986 Sep-Oct;7(5):855–864. doi: 10.1016/0196-9781(86)90106-3. [DOI] [PubMed] [Google Scholar]
  9. Dam T. V., Takeda Y., Krause J. E., Escher E., Quirion R. gamma-Preprotachykinin-(72-92)-peptide amide: an endogenous preprotachykinin I gene-derived peptide that preferentially binds to neurokinin-2 receptors. Proc Natl Acad Sci U S A. 1990 Jan;87(1):246–250. doi: 10.1073/pnas.87.1.246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Drapeau G., D'Orléans-Juste P., Dion S., Rhaleb N. E., Rouissi N. E., Regoli D. Selective agonists for substance P and neurokinin receptors. Neuropeptides. 1987 Jul;10(1):43–54. doi: 10.1016/0143-4179(87)90088-6. [DOI] [PubMed] [Google Scholar]
  11. Elliott P. J., Iversen S. D. Behavioural effects of tachykinins and related peptides. Brain Res. 1986 Aug 27;381(1):68–76. doi: 10.1016/0006-8993(86)90691-8. [DOI] [PubMed] [Google Scholar]
  12. Elliott P. J., Mason G. S., Stephens-Smith M., Hagan R. M. Behavioural and biochemical responses following activation of midbrain dopamine pathways by receptor selective neurokinin agonists. Neuropeptides. 1991 Jun;19(2):119–126. doi: 10.1016/0143-4179(91)90141-5. [DOI] [PubMed] [Google Scholar]
  13. Fardin V., Foucault F., Bock M. D., Jolly A., Flamand O., Clerc F., Garret C. Variations in affinities for the NK1 receptor: differences between the non-peptide substance P antagonists RP 67580 and CP-96,345 and the agonist septide. Regul Pept. 1993 Jul 2;46(1-2):300–303. doi: 10.1016/0167-0115(93)90066-h. [DOI] [PubMed] [Google Scholar]
  14. Fardin V., Garret C. Species differences between [3H] substance P binding in rat and guinea-pig shown by the use of peptide agonists and antagonists. Eur J Pharmacol. 1991 Aug 29;201(2-3):231–234. doi: 10.1016/0014-2999(91)90350-y. [DOI] [PubMed] [Google Scholar]
  15. Garret C., Carruette A., Fardin V., Moussaoui S., Peyronel J. F., Blanchard J. C., Laduron P. M. Pharmacological properties of a potent and selective nonpeptide substance P antagonist. Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10208–10212. doi: 10.1073/pnas.88.22.10208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Geraghty D. P., Burcher E. Two classes of binding sites for [3H]substance P in rat cerebral cortex. Brain Res. 1993 Jan 22;601(1-2):34–40. doi: 10.1016/0006-8993(93)91693-m. [DOI] [PubMed] [Google Scholar]
  17. Gitter B. D., Waters D. C., Bruns R. F., Mason N. R., Nixon J. A., Howbert J. J. Species differences in affinities of non-peptide antagonists for substance P receptors. Eur J Pharmacol. 1991 May 17;197(2-3):237–238. doi: 10.1016/0014-2999(91)90532-u. [DOI] [PubMed] [Google Scholar]
  18. Glowinski J., Kemel M. L., Desban M., Gauchy C., Lavielle S., Chassaing G., Beaujouan J. C., Tremblay L. Distinct presynaptic control of dopamine release in striosomal- and matrix-enriched areas of the rat striatum by selective agonists of NK1, NK2 and NK3 tachykinin receptors. Regul Pept. 1993 Jul 2;46(1-2):124–128. doi: 10.1016/0167-0115(93)90022-z. [DOI] [PubMed] [Google Scholar]
  19. Glowinski J., Torrens Y., Saffroy M., Bergström L., Beaujouan J. C., Lavielle S., Ploux O., Chassaing G., Marquet A. Tachykinin receptors in the CNS. Prog Brain Res. 1987;72:197–203. doi: 10.1016/s0079-6123(08)60208-3. [DOI] [PubMed] [Google Scholar]
  20. Hagan R. M., Beresford I. J., Stables J., Dupere J., Stubbs C. M., Elliott P. J., Sheldrick R. L., Chollet A., Kawashima E., McElroy A. B. Characterisation, CNS distribution and function of NK2 receptors studied using potent NK2 receptor antagonists. Regul Pept. 1993 Jul 2;46(1-2):9–19. doi: 10.1016/0167-0115(93)90005-s. [DOI] [PubMed] [Google Scholar]
  21. Hall J. M., Caulfield M. P., Watson S. P., Guard S. Receptor subtypes or species homologues: relevance to drug discovery. Trends Pharmacol Sci. 1993 Oct;14(10):376–383. doi: 10.1016/0165-6147(93)90096-3. [DOI] [PubMed] [Google Scholar]
  22. Hooper N. M., Kenny A. J., Turner A. J. The metabolism of neuropeptides. Neurokinin A (substance K) is a substrate for endopeptidase-24.11 but not for peptidyl dipeptidase A (angiotensin-converting enzyme). Biochem J. 1985 Oct 15;231(2):357–361. doi: 10.1042/bj2310357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Humpel C., Saria A. Characterization of neurokinin binding sites in rat brain membranes using highly selective ligands. Neuropeptides. 1993 Jul;25(1):65–71. doi: 10.1016/0143-4179(93)90071-h. [DOI] [PubMed] [Google Scholar]
  24. Itoi K., Tschöpe C., Jost N., Culman J., Lebrun C., Stauss B., Unger T. Identification of the central tachykinin receptor subclass involved in substance P-induced cardiovascular and behavioral responses in conscious rats. Eur J Pharmacol. 1992 Sep 4;219(3):435–444. doi: 10.1016/0014-2999(92)90485-m. [DOI] [PubMed] [Google Scholar]
  25. Johnston P. A., Chahl L. A. Tachykinin antagonists inhibit the morphine withdrawal response in guinea-pigs. Naunyn Schmiedebergs Arch Pharmacol. 1991 Mar;343(3):283–288. doi: 10.1007/BF00251127. [DOI] [PubMed] [Google Scholar]
  26. Jolicoeur F. B., Rondeau D. B., Belanger F., Fouriezos G., Barbeau A. Influence of substance P on the behavioral changes induced by haloperidol in rats. Peptides. 1980 Spring;1(1):103–107. doi: 10.1016/0196-9781(80)90042-x. [DOI] [PubMed] [Google Scholar]
  27. Laufer R., Gilon C., Chorev M., Selinger Z. Characterization of a neurokinin B receptor site in rat brain using a highly selective radioligand. J Biol Chem. 1986 Aug 5;261(22):10257–10263. [PubMed] [Google Scholar]
  28. Lavielle S., Chassaing G., Julien S., Marquet A., Bergström L., Beaujouan J. C., Torrens Y., Glowinski J. Specific recognition of SP or NKB receptors by analogues of SP substituted at positions 8 and 9. Eur J Pharmacol. 1986 Jun 24;125(3):461–462. doi: 10.1016/0014-2999(86)90804-6. [DOI] [PubMed] [Google Scholar]
  29. Maggi C. A., Eglezos A., Quartara L., Patacchini R., Giachetti A. Heterogeneity of NK-2 tachykinin receptors in hamster and rabbit smooth muscles. Regul Pept. 1992 Jan 23;37(2):85–93. doi: 10.1016/0167-0115(92)90657-g. [DOI] [PubMed] [Google Scholar]
  30. Maggi C. A., Patacchini R., Astolfi M., Rovero P., Giuliani S., Giachetti A. NK-2 receptor agonists and antagonists. Ann N Y Acad Sci. 1991;632:184–191. doi: 10.1111/j.1749-6632.1991.tb33106.x. [DOI] [PubMed] [Google Scholar]
  31. Maggi C. A., Patacchini R., Meini S., Giuliani S. Evidence for the presence of a septide-sensitive tachykinin receptor in the circular muscle of the guinea-pig ileum. Eur J Pharmacol. 1993 Apr 28;235(2-3):309–311. doi: 10.1016/0014-2999(93)90152-8. [DOI] [PubMed] [Google Scholar]
  32. Maggi C. A., Patacchini R., Rovero P., Giachetti A. Tachykinin receptors and tachykinin receptor antagonists. J Auton Pharmacol. 1993 Feb;13(1):23–93. doi: 10.1111/j.1474-8673.1993.tb00396.x. [DOI] [PubMed] [Google Scholar]
  33. Mason G. S., Elliott P. J. Behavioural consequences following infusion of selective neurokinin agonists into the median raphe nucleus of the rat. Neuropharmacology. 1992 Aug;31(8):757–760. doi: 10.1016/0028-3908(92)90037-p. [DOI] [PubMed] [Google Scholar]
  34. Matsas R., Fulcher I. S., Kenny A. J., Turner A. J. Substance P and [Leu]enkephalin are hydrolyzed by an enzyme in pig caudate synaptic membranes that is identical with the endopeptidase of kidney microvilli. Proc Natl Acad Sci U S A. 1983 May;80(10):3111–3115. doi: 10.1073/pnas.80.10.3111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Matsas R., Kenny A. J., Turner A. J. The metabolism of neuropeptides. The hydrolysis of peptides, including enkephalins, tachykinins and their analogues, by endopeptidase-24.11. Biochem J. 1984 Oct 15;223(2):433–440. doi: 10.1042/bj2230433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. McLean S., Ganong A., Seymour P. A., Snider R. M., Desai M. C., Rosen T., Bryce D. K., Longo K. P., Reynolds L. S., Robinson G. Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor. J Pharmacol Exp Ther. 1993 Oct;267(1):472–479. [PubMed] [Google Scholar]
  37. Merchenthaler I., Maderdrut J. L., O'Harte F., Conlon J. M. Localization of neurokinin B in the central nervous system of the rat. Peptides. 1992 Jul-Aug;13(4):815–829. doi: 10.1016/0196-9781(92)90192-6. [DOI] [PubMed] [Google Scholar]
  38. Mussap C. J., Geraghty D. P., Burcher E. Tachykinin receptors: a radioligand binding perspective. J Neurochem. 1993 Jun;60(6):1987–2009. doi: 10.1111/j.1471-4159.1993.tb03484.x. [DOI] [PubMed] [Google Scholar]
  39. Nakanishi S. Mammalian tachykinin receptors. Annu Rev Neurosci. 1991;14:123–136. doi: 10.1146/annurev.ne.14.030191.001011. [DOI] [PubMed] [Google Scholar]
  40. Naranjo J. R., Del Rio J. Locomotor activation induced in rodent by substance P and analogues. Blockade of the effect of substance P by met-enkephalin antiserum. Neuropharmacology. 1984 Oct;23(10):1167–1171. doi: 10.1016/0028-3908(84)90234-x. [DOI] [PubMed] [Google Scholar]
  41. Nguyen Q. T., Jukic D., Chrétien L., Gobeil F., Boussougou M., Regoli D. Two NK-3 receptor subtypes: demonstration by biological and binding assays. Neuropeptides. 1994 Sep;27(3):157–161. doi: 10.1016/0143-4179(94)90065-5. [DOI] [PubMed] [Google Scholar]
  42. Paris J. M., Lorens S. A. A dose-response analysis of intra-raphe tachykinin-induced hyperactivity. J Pharmacol Exp Ther. 1989 Oct;251(1):388–393. [PubMed] [Google Scholar]
  43. Petitet F., Beaujouan J. C., Saffroy M., Torrens Y., Chassaing G., Lavielle S., Besseyre J., Garret C., Carruette A., Glowinski J. Further demonstration that [Pro9]-substance P is a potent and selective ligand of NK-1 tachykinin receptors. J Neurochem. 1991 Mar;56(3):879–889. doi: 10.1111/j.1471-4159.1991.tb02004.x. [DOI] [PubMed] [Google Scholar]
  44. Petitet F., Beaujouan J. C., Saffroy M., Torrens Y., Fardin V., Glowinski J. NK-1 tachykinin receptor in rat and guinea pig brains: pharmacological and autoradiographical evidence for a species difference. Peptides. 1993 May-Jun;14(3):551–559. doi: 10.1016/0196-9781(93)90144-6. [DOI] [PubMed] [Google Scholar]
  45. Petitet F., Beaujouan J. C., Saffroy M., Torrens Y., Glowinski J. The nonpeptide NK-2 antagonist SR 48968 is also a NK-3 antagonist in the guinea but not in the rat. Biochem Biophys Res Commun. 1993 Feb 26;191(1):180–187. doi: 10.1006/bbrc.1993.1200. [DOI] [PubMed] [Google Scholar]
  46. Petitet F., Saffroy M., Torrens Y., Lavielle S., Chassaing G., Loeuillet D., Glowinski J., Beaujouan J. C. Possible existence of a new tachykinin receptor subtype in the guinea pig ileum. Peptides. 1992 Mar-Apr;13(2):383–388. doi: 10.1016/0196-9781(92)90125-m. [DOI] [PubMed] [Google Scholar]
  47. Picard P., Regoli D., Couture R. Cardiovascular and behavioural effects of centrally administered tachykinins in the rat: characterization of receptors with selective antagonists. Br J Pharmacol. 1994 May;112(1):240–249. doi: 10.1111/j.1476-5381.1994.tb13058.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Pradier L., Ménager J., Le Guern J., Bock M. D., Heuillet E., Fardin V., Garret C., Doble A., Mayaux J. F. Septide: an agonist for the NK1 receptor acting at a site distinct from substance P. Mol Pharmacol. 1994 Feb;45(2):287–293. [PubMed] [Google Scholar]
  49. Ravard S., Betschart J., Fardin V., Flamand O., Blanchard J. C. Differential ability of tachykinin NK-1 and NK-2 agonists to produce scratching and grooming behaviours in mice. Brain Res. 1994 Jul 18;651(1-2):199–208. doi: 10.1016/0006-8993(94)90698-x. [DOI] [PubMed] [Google Scholar]
  50. Regoli D., Drapeau G., Dion S., Couture R. New selective agonists for neurokinin receptors: pharmacological tools for receptor characterization. Trends Pharmacol Sci. 1988 Aug;9(8):290–295. doi: 10.1016/0165-6147(88)90013-2. [DOI] [PubMed] [Google Scholar]
  51. Saffroy M., Beaujouan J. C., Torrens Y., Besseyre J., Bergström L., Glowinski J. Localization of tachykinin binding sites (NK1, NK2, NK3 ligands) in the rat brain. Peptides. 1988 Mar-Apr;9(2):227–241. doi: 10.1016/0196-9781(88)90255-0. [DOI] [PubMed] [Google Scholar]
  52. Sakurada T., Tan-No K., Yamada T., Sakurada S., Kisara K. Phosphoramidon potentiates mammalian tachykinin-induced biting, licking and scratching behaviour in mice. Pharmacol Biochem Behav. 1990 Dec;37(4):779–783. doi: 10.1016/0091-3057(90)90563-w. [DOI] [PubMed] [Google Scholar]
  53. Sakurada T., Yamada T., Sakurada S., Kisara K., Ohba M. Substance P analogues containing D-histidine antagonize the behavioural effects of intrathecally co-administered substance P in mice. Eur J Pharmacol. 1989 Dec 19;174(2-3):153–160. doi: 10.1016/0014-2999(89)90307-5. [DOI] [PubMed] [Google Scholar]
  54. Snider R. M., Constantine J. W., Lowe J. A., 3rd, Longo K. P., Lebel W. S., Woody H. A., Drozda S. E., Desai M. C., Vinick F. J., Spencer R. W. A potent nonpeptide antagonist of the substance P (NK1) receptor. Science. 1991 Jan 25;251(4992):435–437. doi: 10.1126/science.1703323. [DOI] [PubMed] [Google Scholar]
  55. Stoessl A. J., Dourish C. T., Iversen S. D. Pharmacological characterization of the behavioural syndrome induced by the NK-3 tachykinin agonist senktide in rodents: evidence for mediation by endogenous 5-HT. Brain Res. 1990 May 28;517(1-2):111–116. doi: 10.1016/0006-8993(90)91015-9. [DOI] [PubMed] [Google Scholar]
  56. Stoessl A. J., Dourish C. T., Iversen S. D. The NK-3 tachykinin agonist senktide elicits yawning and chewing mouth movements following subcutaneous administration in the rat. Evidence for cholinergic mediation. Psychopharmacology (Berl) 1988;95(4):502–506. doi: 10.1007/BF00172963. [DOI] [PubMed] [Google Scholar]
  57. Stoessl A. J., Dourish C. T., Iversen S. D. The NK-3 tachykinin receptor agonist senktide elicits 5-HT-mediated behaviour following central or peripheral administration in mice and rats. Br J Pharmacol. 1988 Jun;94(2):285–287. doi: 10.1111/j.1476-5381.1988.tb11527.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Stoessl A. J., Dourish C. T., Young S. C., Williams B. J., Iversen S. D., Iversen L. L. Senktide, a selective neurokinin B-like agonist, elicits serotonin-mediated behaviour following intracisternal administration in the mouse. Neurosci Lett. 1987 Oct 5;80(3):321–326. doi: 10.1016/0304-3940(87)90475-7. [DOI] [PubMed] [Google Scholar]
  59. Stoessl A. J., Szczutkowski E., Glenn B., Watson I. Behavioural effects of selective tachykinin agonists in midbrain dopamine regions. Brain Res. 1991 Nov 29;565(2):254–262. doi: 10.1016/0006-8993(91)91657-m. [DOI] [PubMed] [Google Scholar]
  60. Tschöpe C., Picard P., Culman J., Prat A., Itoi K., Regoli D., Unger T., Couture R. Use of selective antagonists to dissociate the central cardiovascular and behavioural effects of tachykinins on NK1 and NK2 receptors in the rat. Br J Pharmacol. 1992 Nov;107(3):750–755. doi: 10.1111/j.1476-5381.1992.tb14518.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Unger T., Carolus S., Demmert G., Ganten D., Lang R. E., Maser-Gluth C., Steinberg H., Veelken R. Substance P induces a cardiovascular defense reaction in the rat: pharmacological characterization. Circ Res. 1988 Oct;63(4):812–820. doi: 10.1161/01.res.63.4.812. [DOI] [PubMed] [Google Scholar]
  62. Wormser U., Laufer R., Hart Y., Chorev M., Gilon C., Selinger Z. Highly selective agonists for substance P receptor subtypes. EMBO J. 1986 Nov;5(11):2805–2808. doi: 10.1002/j.1460-2075.1986.tb04571.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES